UCB S A/ADR (OTCMKTS:UCBJY) saw a significant increase in short interest in September. As of September 15th, there was short interest totalling 4,100 shares, an increase of 720.0% from the August 31st total of 500 shares. Based on an average daily trading volume, of 10,900 shares, the short-interest ratio is presently 0.4 days.
UCB S A/ADR stock opened at $57.23 on Monday. The business’s 50-day simple moving average is $58.96 and its 200-day simple moving average is $52.85. UCB S A/ADR has a 52 week low of $32.45 and a 52 week high of $68.00.
UCBJY has been the topic of several recent research reports. UBS Group lowered UCB S A/ADR from a “buy” rating to a “neutral” rating in a report on Friday, July 31st. JPMorgan Chase & Co. reiterated an “overweight” rating on shares of UCB S A/ADR in a research note on Tuesday, July 28th.
UCB S A/ADR Company Profile
UCB SA, a biopharmaceutical company, researches, develops, manufactures, sells, and distributes biopharmaceutical solutions for people living with neurology and immunology conditions. The company's core products include Cimzia for inflammatory TNF mediated diseases, as well as ankylosing spondylitis, axial spondyloarthritis, Crohn's disease, plaque psoriasis, psoriatic arthritis, and rheumatoid arthritis; Vimpat, Keppra, and Briviact for epilepsy; and Neupro for Parkinson's disease and restless legs syndrome.
Featured Article: What is a Reverse Stock Split?
Receive News & Ratings for UCB S A/ADR Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for UCB S A/ADR and related companies with MarketBeat.com's FREE daily email newsletter.